A Phase 4 interventional study of Cytisinicline and exercise and Cytisinicline in Smoking Cessation, sponsored by Maimónides Biomedical Research Institute of Córdoba. Not yet recruiting. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-04.
Sponsored by Maimónides Biomedical Research Institute of Córdoba · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing cytisine in Smoking Cessation — 3 open to participants now, 5 under way, 1 of them phase 3. cytisine · Smoking Cessation.
Among the 22 studies testing cytisine in Smoking Cessation, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 3 in phase 4, and was the 20th registered.
1,583 studies on the registry are indexed under Smoking Cessation; 196 are open to participants now.
Browse Smoking Cessation studies →3 of the 22 studies testing cytisine in Smoking Cessation are open now, in 1 country. Recruiting first, the newest first:
University of California, Los Angeles · Sites in United States
Ages 18–65
Centre for Addiction and Mental Health
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 134 Smoking Cessation studies recruiting now, 92 (69%) set no upper age limit and 35 (26%) stop at 75 or younger; 6 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 4 · Phase 3 7 · Phase 4 3
First in 2016; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 163 across 1,425 interventional studies indexed under Smoking Cessation.
Median enrollment 202 across the 22 interventional studies. Of the 17 that completed or were terminated, 7 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 22 have an industry lead sponsor. The 10 most frequent:
Maimónides Biomedical Research Institute of Córdoba is the lead sponsor of 79 studies on the registry; 19 are open to participants now.
Maimónides Biomedical Research Institute of Córdoba has 1 study filed under Smoking Cessation — fewer than ten, so there is no comparison to draw.
1 of the studies testing cytisine in Smoking Cessation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06617312University of California, Los AngelesExamining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies testing cytisine in Smoking Cessation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Current scientific evidence demonstrates the relationship between good physical fitness and a lower incidence of certain chronic diseases, including smoking, as well as the effectiveness of cytisinicline. This protocol aims to evaluate the efficacy of the synergistic effect of combining structured physical exercise, brief counseling, and cytisinicline administration in achieving smoking cessation. The study will be an experimental, multicenter, randomized, and controlled trial with two parallel arms, conducted by a multidisciplinary team within the primary care setting of the Andalusian public health system, with a 12-month follow-up. The estimated sample size is 75 participants per arm. One of the study arms will include a structured exercise program aligned with the recently approved regional Andalusian health plan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Smokers who will receive directed physical exercise and brief counseling while undergoing treatment according to the care process.
Drug: Cytisinicline and exercise
Smokers who will receive an informational leaflet and brief counseling when they begin cytisinicline treatment, according to the care process.
Drug: Cytisinicline
Drug page: CytisineStudies of CytisineCytisine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Doctors will provide brief, personalized counseling anti-smoking plan. This counseling will support smokers in the determination-action phase of behavior change. Physicians will administer cytisine as follows: 1 tablet every 2 hours (maximum 6 per day) from days 1-3; every 2.5 hours (maximum 5 per day) from days 4-12; every 3 hours (maximum 4 per day) from days 13-16; every 5 hours (maximum 3 per day) from days 17-20; and 1-2 tablets per day (maximum 2 per day) from days 21-25. Participants will follow a combined aerobic and strength exercise program. This includes at least 150 minutes of moderate-intensity aerobic physical activity per week, or 75 minutes of vigorous-intensity aerobic activity, or an equivalent combination of both. Aerobic activity should be performed in sessions lasting at least 10 minutes.
Also known as: Cytisinicline, Exercise
Same intervention as the experimental group without directed exercise prescription
Smoking
Number of cigarettes smoked daily.
Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365
Smoking cessation
Dichotomous variable (yes/not) asking in the clinical history.
Time frame: Day 30; Day; 60; Day 90; Day 180; Day 365
Carbon monoxide exhaled air
Carbon monoxide in the subject's exhaled air. It will be measured with a Co-oximeter of the brand "Co Check", code 01PLS18B, with a sensitivity of 1 ppm and accuracy (repeatability) of 2%. The unit of measurement of the variable is parts per million (ppm).
Time frame: Day 0; Day 30; Day; 60; Day 90; Day 180; Day 365
Blood pressure
Blood pressure is measured in the non-dominant arm three times, with a 5-minute gap between each measurement, using an automatic oscillometer (Omron M3 Intellisense HEM-75051-EV; IOMRON Healthcare Europe) equipped with a child-specific cuff. The average of the three measurements is recorded for both systolic and diastolic blood pressure. The mean blood pressure values are expressed in mmHg.
Time frame: Day 0; Day 30; Day; 60; Day 90; Day 180; Day 365
Weight
Weight in grams is measured by the precision weighing scale model Tanita 780PMA.
Time frame: Day 0; Day 30; Day; 60; Day 90; Day 180; Day 365
Body mass index
Body mass index in kilograms per square meter is calculated.
Time frame: Day 0; Day 30; Day; 60; Day 90; Day 180; Day 365
Physical dependence on nicotine
Physical dependence on nicotine measured by the Fagerström Test for Nicotine Dependence (FTND). This test consists of 6 questions, and each question has response options with assigned scores. The total score is the sum of the response scores and ranges from 0 to 10 points. The scoring scale is interpreted as follows: 0-2 points: Low dependence. 3-4 points: Low to moderate dependence. 5 points: Moderate dependence. 6-7 points: High dependence. 8-10 points: Very high dependence.
Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365
Psychological dependence on smoking
Physical dependence on nicotine measured by the Glover-Nilsson Smoking Behavioral Questionnaire (GN-SBQ). The GN-SBQ consists of 11 questions, each with response options ranging from 0 (never) to 4 (always), forming a 5-point Likert scale. The total test score is obtained by summing the responses to all the questions, resulting in a possible score range of 0 to 44 points. The scores are interpreted as follows: 0-10 points: Low behavioral dependence on tobacco. 11-22 points: Moderate behavioral dependence. 23-33 points: High behavioral dependence. 34-44 points: Very high behavioral dependence.
Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365
Motivation to quit smoking
Physical dependence on nicotine measured by the Richmond Smoking Withdrawal Questionnaire. This test consists of 4 questions. Each question has response options with scores ranging from 0 to 3 points. The total score is obtained by summing the responses, resulting in a possible range of 0 to 10 points. The interpretation of the scores is as follows: 0-3 points: Low dependence on nicotine. 4-5 points: Moderate dependence. 6-7 points: High dependence. 8-10 points: Very high dependence.
Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365
Alcohol consumption
Weekly alcohol consumption. Unit of measurement is Standard Drink Units
Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365
Physical activity
Time physical activity performed daily will be measured with the Global Physical Activity Questionnaire (GPAQ) of the World Health Organization (WHO). It collects quantitative information on physical activity in three different domains: 1) Physical activity at work (including occupational activity and domestic work); 2)Transport (physical activity related to transportation, such as walking or cycling); 3) Recreational physical activity (sports, exercise, leisure). For each of these domains, the GPAQ asks respondents about the frequency (days per week) and duration (minutes per day) of the physical activities performed. Additionally, the GPAQ also inquires about the time spent on sedentary activities. The collected information is used to calculate the respondent's level of physical activity, which is categorized into levels such as low, moderate, or high physical activity according to WHO guidelines.
Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365
Self-efficacy for physical activity
Self-efficacy for physical activity measured by the Benisovich Test. The scale used in this test is an 11-point Likert scale, ranging from 0 to 10, where: 0 indicates "not confident at all" or "I have no confidence at all that I could do this." 10 indicates "completely confident" or "I have complete confidence that I could do this."
Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365
Heart rate in rest
The unit of measure is beats per minute (bpm).
Time frame: Day 0; Day 7; Day 30; Day; 60; Day 90; Day 180; Day 365
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Dec 2025, 11 months later.
Of 53 non-industry phase 4 interventional studies under Smoking Cessation, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 11 months is below that.
Counting every sponsor, half of 56 studies reached it within 35 months; a quarter within 21 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytisine
Maimónides Biomedical Research Institute of Córdoba